Abstract
Children suffering from thalassaemia major are reported to have growth delay and bone alterations even when well transfused and chelated. In the present study we evaluated bone and collagen turnover (bone Gla-protein, BGP; carboxyterminal telopeptide of type I collagen, ICTP; aminoterminal propeptide of type III procollagen, PIIINP, respectively) and bone mineral density (BMD) in 5 pre-pubertal GH deficient thalassaemic children before and during rec-GH treatment (0.6 IU/kg/week). Data were compared with those recorded in an age- and sex-matched control group. Before treatment, serum BGP and ICTP levels were significantly lower (p<0.0001) in children with thalassaemia (9.3±0.7 ng/ml and 5.3±0.5 ng/ml, respectively) than in healthy controls (18.9±0.9 ng/ml and 14.4±0.6 ng/ml, respectively), while serum PIIINP levels did not significantly differ in the two groups (6.7±0.7 ng/ml vs 6.7±0.7 ng/ml). Mean lumbar BMD values of patients (0.62±0.05 g/cm2) were significantly lower (p<0.05) than those recorded in healthy controls (0.78±0.01 g/cm2), while femoral BMD values were similar in the two groups (patients: 0.70±0.08 g/cm2 vs controls: 0.74±0.01 g/cm2). One-year GH therapy significantly increased height velocity (from 2.3±0.2 cm/year to 6.1±0.4 cm/yr, p<0.0001) and IGF-I levels (from 61.6±15.4 to 342±38.5 ng/ml, p<0.005). Serum BGP (basal: 9.3±0.7 ng/ml, 6th month: 10.8±0.6 ng/ml, 12th month: 14.9±1.4 ng/ml), ICTP (basal: 5.3±0.5 ng/ml, 6th month: 7.9±0.8 ng/ml, 12th month: 10.9±1.7 ng/ml) and PIIINP levels (basal: 6.7±0.7 ng/ml, 6th month: 9.9±1.0 ng/ml, 12th month: 9.6±1.4 ng/ml) significantly increased (p<0.05), while no significant effects were observed on lumbar and femoral BMD values. Although the GH-induced stimulation of bone turnover markedly increased BGP (+60%) and ICTP (+105%) levels, one-year GH therapy was not sufficient to completely normalize these parameters, which remained significantly lower than in healthy controls. In conclusion, our study shows that pre-pubertal GH deficient children with thalassaemia major have reduced bone turnover (both bone formation and resorption) and lumbar BMD values, thus indicating that bone metabolism should be monitored and improved even in well-transfused patients. One-year GH treatment is able to increase, but not normalize, bone turnover, this effect being insufficient to improve BMD values. More prolonged periods of GH therapy are probably requested to positively affect both bone turnover and BMD values in GH deficient thalassaemic patients, as occurs in children and adults with GH deficiency.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Orvieto R., Leichter I., Rachmilewitz A., Margulies J.Y. Bone density, mineral content, and cortical index in patients with thalassaemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine. Calcif. Tissue Int. 1992, 50: 397–399.
Lala R., Chiabotto P., Di Stefano M., Isaia G.C., Garofalo F., Piga A. Bone density and metabolism in thalassemia. J. Pediatr. Endocrinol. Metab. 1998, 11: 785–790.
Clegg J.B., Weatherall D.J. The Thalassaemia Syndrome, ed. 3. Blackwell Scientific, Oxford, UK, 1985, p. 157.
Bisbocci D., Livorno P., Modina P., Gambino M., Damiano P., Cantoni R., Villata E., Chiandussi L. Osteodystrophy in thalassaemia major. Ann. Ital. Med. Int. 1993, 8: 224–226.
Filosa A., Di Maio S., Vocca S., Saviano A., Esposito G., Pagano L. Longitudinal monitoring of bone mineral density in thalassaemic patients. Genetic structure and osteoporosis. Acta Paediatr. 1997, 86: 342–346.
Costin G., Kogut M.D., Hyman C.B., Ortega J.A. Endocrine abnormalities in thalassaemia major. Am. J. Dis. Child. 1979, 133: 497–502.
Borgna-Pignatti C., De Stefano P., Zonta L. Growth and sexual maturation in thalassaemia major. J. Pediatr. 1985, 106: 150–155.
El Hazmi M.A.F., Warsy A.S., AL Fawaz I. Iron-endocrine pattern in patients with β-thalassaemia J. Trop. Pediatr. 1994, 40: 219–224.
De Simone M., Di Bartolomeo P., Olioso P., Di Girolamo G., Palumbo M., Farello G., Aconito P., Papalinetti G., Bavaro P., Criscione S. Growth after recombinant human growth hormone (rhGH) treatment in transplanted thalassaemic patients. Bone Marrow Transplant 1997, 20: 567–573.
Roth C., Pekrun A., Bartz M., Jarry H., Eber S., Lakomek M., Schröter W. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur. J. Paediatr. 1997, 156: 777–783.
Low L.C.K., Poster-Vinay M.C., Kwan E.Y.W., Cheung P.T. Serum growth hormone (GH) binding protein, IGF-I, and IGFBP-3 in patients with β-thalassaemia major and the effect of GH treatment. Clin. Endocrinol. (Oxf.) 1998, 48: 641–646.
Cavallo L., Gurrado R., Zecchino C., Manolo F., De Sanctis V., Cisternino M., Caruso-Nicoletti M., Galati M. Short-term therapy with recombinant growth hormone in polytranfused thalassaemia major patients with growth deficiency. J. Pediatr. Endocrinol. Metab. 1998, 11: 845–849.
Theodoridis C., Ladis V., Papatheodorou A., Berdousi H., Palamidou F., Evagelopoulou C., Athanassaki K., Konstantoura O., Kattamis C. Growth and management of short stature in thalassaemia major. J. Pediatr. Endocrinol. Metab. 1998, 11: 844–853.
Soliman A.T., El Banna N., Fattah M.A., El Zalabani M.M., Ansari B.M. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism 1998, 47: 541–548.
Shore R.M., Chesney R.W., Mazess R.B., Rose P.G., Bargman G.J. Bone mineral status in growth hormone deficiency. J. Pediatr. 1980, 96: 393–396.
Johansen J.S., Giwercman A., Hartwell D., Nielsen C.T., Price P.A., Christiansen C., Skakkebaek N.E. Serum bone-Gla protein as a marker of bone growth in children and adolescents: correlation with age, height, serum insulin-like growth factor I, and serum testosterone. J. Clin. Endocrinol. Metab. 1988, 67: 273–278.
Sartorio A., Conti A., Guzzaloni G., Faglia G. Serum osteocalcin levels in patients with GH deficiency before and during GH treatment. Acta Pediatr. Scand. 1991, 80: 100–102.
Sartorio A., Conti A., Monzani M. New markers of bone and collagen turnover in children and adults with growth hormone deficiency. Postgrad. Med. J. 1993, 69: 846–850.
Kaufman J.M., Taelman P., Vermeulen A., Vandeweghe M. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J. Clin. Endocrinol. Metab. 1992, 74: 118–123.
Balducci R., Toscano V., Pasquino A.M., Mangiantini A., Municchi G., Armenise P., Terracina S., Prossomariti G., Boscherini B. Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapy. Eur. J. Endocrinol. 1995, 132: 42–46.
Sartorio A., Ortolani S., Conti A., Cherubini R., Galbiati E., Faglia G. Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency. J. Endocrinol. Invest. 1996, 19: 524–529.
Ohlsson C., Bengtsson B., Isaksson O.G.P., Andreassen T.T., Slootweg M.C. Growth hormone and bone. Endocr. Rev. 1998, 19: 55–79.
Baum H.B.A., Biller B.M.K., Finkelstein J.S., Cannistraro K.B., Oppenheim D.S., Schoenfeld D.A., Michel T.H., Wittink H., Klibanski A. Effect of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann. Intern. Med. 1996, 125: 883–890.
Johannsson G., Rosen T., Bosaeus I., Sjostrom L., Bengtsson B.A. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J. Clin. Endocrinol. Metab. 1996, 81: 2865–2873.
Sartorio A., Arosio M., Conti A., Ferrero S., Porretti S., and Faglia G. Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency. J. Endocrinol. Invest. 1999, 22: 169–175.
Sartorio A., Conti A., Ferrero S., Saraifoger S., Resnik M., Baroncelli G.I. Effects of 12-months rec-GH treatment on bone and collagen turnover in children with constitutional growth delay. J. Pediatr. Endocrinol. Metab. 1999, 12: 833–838.
Holmes S.J., Whitehouse R.W., Swindell R., Economou G., Adams J.E., Shalet S.M. Effects of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin. Endocrinol. (Oxf.) 1995, 42: 627–633.
Hansen T.B., Brixen K., Vahl N., Jorgensen J.O., Christiansen J.S., Mosekilde L., Hagen C. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double-blind, randomized, placebocontrolled study. J. Clin. Endocrinol. Metab. 1996, 81: 3352–3359.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sartorio, A., Conte, G., Conti, A. et al. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major. J Endocrinol Invest 23, 356–361 (2000). https://doi.org/10.1007/BF03343738
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343738